The Direct-to-Consumer Price War

With compounded copies curbed, the branded giants are fighting on cash price. The tiebreaker, at last, is the patient.

For two years, the cheapest way to get a GLP-1 drug ran through a compounding pharmacy. That route has narrowed sharply, and a new contest has opened in its place: the branded manufacturers selling straight to cash-paying patients, undercutting each other dose by dose. GLP-1 direct pricing is now a competitive weapon, not an afterthought.

The new battlefield

Two channels anchor the fight. Eli Lilly’s LillyDirect and Novo Nordisk’s NovoCare let patients buy the real, branded medicine — the manufacturer’s own pen or vial — without going through the traditional insurance-and-pharmacy gauntlet. The pitch is simple: authentic product, transparent cash price, shipped to your door.

Lilly cut its Zepbound multidose pen to around $299 a month for the lowest dose, rising toward $449 for higher ones — roughly $50 below prior direct prices. Novo matched the logic through its own channel. The November 2025 pricing deal layered on TrumpRx as an additional discount storefront, pulling cash prices for the leading injectables toward $350 and, over two years, toward $245.

Why compounding’s end lit the fuse

The timing is not a coincidence. During the shortage, compounded semaglutide and tirzepatide sold for $150 to $300 a month, and they set the market’s price expectations. Patients grew accustomed to paying far below the list price. When the FDA wound down compounding as the shortages resolved, the branded manufacturers faced a choice: watch those price-sensitive patients drop off, or compete for them directly.

They chose to compete. Branded direct pricing does not fully match the prices of the cheapest compounded vials. Still, it closes much of the gap — and it does so with a product whose identity, purity, and dosing come guaranteed by the maker, not by an unregulated powder.

The trade patients weigh

The decision now facing many patients is convenience and assurance against price. A prefilled pen from the actual manufacturer removes the risks that dogged compounded vials — dosing errors, uncertain concentration, questionable sourcing. However, it still costs somewhat more than the gray-market low. For some, the peace of mind is worth the premium; for others, the math is tight.

What has changed is that the branded option is now within reach for far more people than a year ago. A $299 to $349 cash price is a different proposition than a $1,000 list price, even if it is not $150.

Why it matters

This is competition doing what regulation alone could not: dragging a four-figure list price downward through the simple pressure of two well-matched rivals chasing the same enormous patient pool. Neither company wants to cede the cash-pay market to the other, and that rivalry benefits the buyer.

The gray market offered cheap access at real risk. The branded price war is an attempt to offer cheaper access without the risk — and to keep patients inside the legitimate supply chain, where the manufacturers can serve them directly and repeatedly.

What it means

For patients, the practical move is to compare all the routes now available: LillyDirect or NovoCare cash pricing, TrumpRx, and whatever a commercial or Medicare plan offers, since the same drug can carry very different prices depending on how you buy it. The era when compounding was the only affordable path is over. In its place is a genuine price war among the branded products — and, for the first time, the patient is the one being competed for.

Frequently asked questions

What is LillyDirect? Eli Lilly’s direct-to-patient channel, where people can buy branded Zepbound at a cash price without going through traditional insurance and pharmacy steps. Novo Nordisk runs a parallel channel, NovoCare, for Wegovy.

How much is Zepbound out-of-pocket? Through LillyDirect, the lowest-dose multidose pen runs around $299 a month, rising toward $449 for higher doses. The November 2025 pricing deal and TrumpRx add further discounts, pulling leading injectables toward $245 over time.

Is branded now cheaper than compounded GLP-1? Not quite at the very lowest compounded prices, but the gap has narrowed sharply — and branded products come with guaranteed identity, purity, and dosing that unregulated compounded vials cannot promise. With compounding largely wound down, direct branded pricing is now the affordable, legitimate route for most patients.

Sources

1. Eli Lilly and Company — LillyDirect self-pay pricing for Zepbound, 2025–2026.
2. Novo Nordisk A/S — NovoCare direct pricing for Wegovy, 2025–2026.
3. The White House — GLP-1 pricing agreement and TrumpRx, November 6, 2025.
4. CNBC and Reuters — reporting on GLP-1 direct-to-consumer pricing, 2025–2026.
5. U.S. Food and Drug Administration — resolution of GLP-1 shortages and wind-down of compounding, 2025.